TG Therapeutics, Inc.TGTXNASDAQ

Revenue (LTM)

$616M

+87.3% YoY

Net Income (LTM)

$447M

+1812.4% YoY

Free Cash Flow

$-25M

Revenue CAGR (5Y)

+426.7%

—Marginsstable

FCF($0.0B)

Profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	7	3↓58.4%	234↑8290.0%	329↑40.8%	616↑87.3%
Gross Profit	6	3↓57.3%	220↑8611.5%	291↑32.3%	515↑77.4%
Operating Income	-345	-218↑36.7%	21↑109.5%	42↑103.2%	123↑194.1%
Net Income	-348	-224↑35.7%	13↑105.7%	23↑84.5%	447↑1812.4%
EBITDA	-342	-213↑37.7%	26↑112.2%	50↑91.2%	134↑169.2%
EPS Diluted	-2.63	-1.46↑44.5%	0.09↑105.8%	0.15↑75.8%	2.77↑1746.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	299	102↓65.8%	93↓9.2%	180↑93.6%	79↓56.0%
Total Current Assets	331	168↓49.2%	318↑88.9%	566↑78.1%	631↑11.4%
Total Assets	380	194↓49.0%	330↑70.3%	578↑75.3%	1,063↑84.1%
Total Current Liabilities	65	53↓18.6%	54↑1.0%	91↑68.8%	154↑69.6%
Total Liabilities	142	135↓5.3%	169↑25.3%	355↑110.1%	415↑16.9%
Total Equity	237	59↓75.3%	161↑174.0%	222↑38.5%	648↑191.4%
Total Debt	79	83↑5.1%	111↑33.4%	254↑129.0%	261↑2.8%
Net Debt	-220	-19↑91.2%	18↑192.8%	74↑313.3%	182↑146.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-296	-176↑40.4%	-31↑82.2%	-41↓29.0%	-25↑38.9%
Capital Expenditure	-0	-0↑96.5%	0	-0	-0↓375.6%
Free Cash Flow	-296	-176↑40.5%	-31↑82.2%	-41↓29.1%	-25↑38.4%
Stock-Based Comp	61	19↓68.7%	38↑97.7%	43↑12.1%	65↑52.0%
Net Change in Cash	-255	-197↑22.8%	-9↑95.2%	87↑1029.3%	-101↓215.8%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance